Insulin and Hemodyalysis in SES

Methods
The Cypher stent Japan Post-Marketing Surveillance (Cypher J-PMS) is a post-marketing surveillance registry aimed at evaluating the safety and efficacy of SES in routine daily practice in the Japanese population. A total of 2,050 consecutive patients who underwent SES deployment were registered from September 2004 through September 2005 at 50 sites throughout Japan. The use of DES was left to each operators' discretion (which included off-label use of the product). SES deployment was performed according to standard interventional techniques. The post procedural antiplatelet regimen consisted of lifelong aspirin (81-162 mg/day) and ticlopidine (200 mg/day for more than 3 months). Angiographic follow up was mandated at 8 months, and clinical follow up was scheduled every year up to 5 years.
The diagnosis of DM was based on the need for treatment with insulin or oral hypoglycemic drugs or a confirmed elevated blood glucose level. DM was present in 889 patients accounting for 43.3% of the overall population. DM patients were further divided into 2 groups based on the status of treatment (insulin-treated diabetes (IT) group: n=207, noninsulin-treated diabetes (NIT) group: n=682). Clinical efficacy and safety were compared among the 2 groups. This study was approved by the Institutional Review Boards of participating institutions.
Clinical Follow up
The primary end-point of this study was the composite outcome of a major adverse cardiac event (MACE) at 3 years. MACE was defined as death by any cause, non-fatal MI, emergent bypass surgery, and target-lesion revascularization (TLR) at 3 years. TLR was defined as coronary artery bypass grafting (CABG) or repeat PCI procedure at the original lesion site including the area inside the stent and the 5-mm vessel segments adjacent to it, and a target vessel-revascularization (TVR) as PCI or CABG of the treated vessel. Stent thrombosis was evaluated by the Academic Research Consortium (ARC) definition using the definite/confirmed and probable categories. Target-vessel failure (TVF) was defined as the composite of cardiac death, non-fatal MI, and targetvessel revascularization in the same epicardial vessel. Clinical outcome at 3 years was determined during outpatient clinic visits or by telephone interviews.
Statistical Analysis
Continuous variables were expressed as mean ± standard deviation and categorical data were presented as frequencies. For comparisons between groups, Fisher's exact test or an ANOVA test was used as appropriate. Both TLR and MACE rates during the follow-up period were analyzed by the Kaplan-Meier method. A log-rank test was used for survival comparisons. Multivariable Cox proportional hazards regression model with a step-wise selection process and an entry/exit criterion of 0.20 was used to examine the predictors and adjusted hazard ratios for MACE and TLR. A P value <0.05 was considered statistically significant.
Results
Patient Demographics
Patient demographics are shown in Table 1 . The IT group was significantly younger than the NIT group. Although there was no difference in the proportion of patients who had a history of coronary artery revascularization, multi-vessel disease was more frequently observed in the IT group. Furthermore, patients with low left ventricle ejection fraction (LVEF) and hemodialysis patients were more frequently observed in the IT group.
Lesion Characteristics
Lesion characteristics are shown in Table 2 . There were no significant differences in the proportions of lesion morphology types according to the AHA/ACC classification. Furthermore, there was no significant difference in the frequency of lesion morphology such as severe calcification, bifurcation and ostial lesion. Table 3 . The MACE rates in the IT group and the NIT group were 26.0% and 14.5%, respectively (P<0.001). Differences in MACE rates were mainly driven by differences in TLR and death rates. There was no difference in non-target-lesion TVR, and the rates of stent thrombosis in the IT group and the NIT group were 0.00% and 1.08%, respectively (P=0.208). Table 4 . Multivariate analysis suggested that hemodialysis and insulintreated DM were independent predictors for MACE (P<0.001 and 0.033, respectively). Furthermore, insulin-treated DM and long lesions (lesion length >30 mm) were independent predictors for TLR (P<0.001, 0.043 and 0.043, respectively).
Predictors of MACE Predictors of MACE and TLR are shown in
Discussion
The main findings of the present analysis are: (1) DM patients who were treated with insulin were associated with higher mortality and required more frequent TLR, and also TVF; (2) however, there were no significant differences in the incidence of stent thrombosis at 3 years; and (3) hemodialysis and insulin-treated DM was a strong independent predictor of mortality treated by SES, and also an independent predictor of TLR in DM patients. Although these findings suggest that SES deployment for DM patients is safe, they call for special attention in DM patients who require both insulintreatment and hemodialysis.
Outcomes of DES in Diabetic Patients
Recent trials demonstrated the clinical efficacy of DES compared to BMS in broad samples of patients with and without DM. 9-11 A randomized study further confirmed the beneficial effects in reducing repeat PCI due to restenosis in both insulin-treated and non insulin-treated DM patients (DIABETES study). 12 These findings have accelerated the expansion of the indication of DES to not only complex lesion morphologies but also difficult clinical sequelae as in the case of diabetic patients. Recent papers indicated that DES are associated with late stent thrombosis, 7 and DM is itself a risk factor. 8 It has also been shown that DM remains a significant risk factor of TLR following both BMS and DES deployment. 13 Therefore, attention has been paid to the safety of DES especially for off-label indications. To elucidate the benefits of DES, long-term follow-up data in real world practice is mandatory. We confirmed the widespread use of DES for off-label indications including in-stent restenosis, bifurcation lesion, and chronic total occlusion. More than 80% of cases in this analysis were off-label usage of DES representing a real world practice. In the present study, the 3-year MACE rate was 26% in the IT group and 14.5% in the NIT group. Multivariate analysis revealed that insulintreated DM was a significant independent predictor of both MACE and TLR. These findings might clearly demonstrate the differences in DES efficacy within DM patients and seems to be consistent with recently published data. In the NHLBI registry, the overall beneficial effect of DES in reducing TLR was demonstrated in both insulin-treated and non-insulin treated DM patients, as compared to BMS. However, no differences in death and MI risk was noted between DES and BMS in insulin-treated DM patients. 14 Ortolani et al demonstrated that the use of DES for DM patients was associated with a reduced 2-year MACE rate compared to BMS. However, this beneficial effect was limited to noninsulin dependent DM patients. 15 In the IT group, MACE mainly contributed to the death rate and TLR. The complete revascularization rate might affect long-term outcomes, however, there was no difference between both groups in this sub-study. Although the IT group was younger than the NIT group, it was associated with morbidities such as low LVEF, multi-vessel disease, and hemodialysis more frequently than the NIT group. These differences in clinical demographics are likely to explain the worthy prognosis in the IT group. Another important point of this study was that the efficacy of SES was significantly attenuated in the IT group compared to the NIT group. There was no difference in angiographic features including vessel size, lesion length, and lesion morphology between the 2 groups, and multivariate analysis showed that insulin-treated DM and hemodialysis were independent predictors for TLR. These findings might suggest that pathophysiological aspects such as renal dysfunction and insulin-treated DM might highly affect the efficacy of SES. Another explanation is that vessel calcification associated with these circumstances contributed to stent malapposition and insufficient drug delivery. However, it is difficult to pinpoint an exact explanation and further investigation is warranted to assess the attenuated efficacy of SES in insulin-treated DM patients. Surprisingly, there was no difference with respect to the rate of non-target-lesion TVR. A clear explanation of this finding is difficult and further investigation seems to be required. However, these findings might support the poor long-term outcomes in DM patients after DES treatment 16 and also support the recent investigation that failed to demonstrate the beneficial effect of PCI followed by optimal medical treatment compared to optimal medical treatment. 17, 18 The combination of optimal PCI and optimal medical treatment might be the next step to overcome the inferiority of long-term outcomes in DM patients.
Safety of SES in Diabetic Patients
Concerns related to DES stent thrombosis have emerged. In this analysis, stent thrombosis was approximately 1% at 3 years and there was no difference in the incidence of stent thrombosis between the 2 groups. Furthermore, the use of dual antiplatelet therapy was limited to approximately 40% in our cohort. These findings suggest the safety of DES. In a previous report, DM was reported to be an independent predictor for stent thrombosis. 19 Iakovou et al reported that DM 21 Further study is warranted to confirm the safety of DES for DM patients in a real-world practice.
Study Limitations
This subset study has several important limitations. First, this is a non-randomized observational study. Second, we could not correctly examine the influence of glycemic control on rates of restenosis and revascularization. It has been known that angiographic follow up might influence revascularization rates because of angiographically driven revascularization, especially in patients with diabetes and hemodialysis. Therefore, the present study that mandated angiographic follow up might underestimate the clinical significance of SES. Finally, because there are no comparative data available, we could not confirm the impact of ethnicity on our results.
Conclusions
DM patients who were treated with insulin were associated with higher mortality and required more frequent TLR, and also TVF; however, there were no significant differences in the incidence of stent thrombosis at 3 years. Hemodialysis and insulin-treated DM were strong independent predictors of mortality when SES was used, and also of TLR in DM patients. Special attention to patients treated with hemodialysis and insulin treatment warranted in the setting of SES deployment though this sub-study suggests the safety of SES deployment for DM patients.
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